Search
Pectin
go.drugbank.com/drugs/DB11158ApprovedInvestigationalVet approvedThis status allows pectin to be used with no limitations.[L1960]
Mixtures: NEO ASTA, NEO DIAFORMCefepime
go.drugbank.com/drugs/DB01413ApprovedInvestigational[A2457,A249050] Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as _Pseudomonas aeruginosa_, and is also indicated for the empirical … Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics.
Neostigmine
go.drugbank.com/drugs/DB01400ApprovedInvestigationalVet approvedNeostigmine, unlike physostigmine, does not cross the blood-brain barrier. … A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine.
Synonyms: 3-Trimethylammoniumphenyl N,N-dimethylcarbamateViltolarsen
go.drugbank.com/drugs/DB15005ApprovedInvestigationalViltolarsen was developed by Nippon Shinyaku Co LTD and is being marketed under the name VILTEPSO™.[L15526] … Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function
Certolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigational[A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819] … [A176606] Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be
Pheniramine
go.drugbank.com/drugs/DB01620ApprovedPheniramine's use as an anti-allergy medication has largely been supplanted by second-generation antihistamines such as [cetirizine] and [loratadine]. … Pheniramine is a first-generation antihistamine in the alkylamine class, similar to [brompheniramine] and [chlorpheniramine].
Mixtures: Neo Citran Powder, Neo Citran A PowderVildagliptin
go.drugbank.com/drugs/DB04876ApprovedInvestigational[A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are incretin hormones that promote … [A232488] Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment of type II diabetes mellitus in adults as monotherapy or in combination with [metformin], a sulfonylurea
Abciximab
go.drugbank.com/drugs/DB00054ApprovedWithdrawnAbciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules … It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Telisotuzumab vedotin
go.drugbank.com/drugs/DB15104ApprovedInvestigational[L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment … [L53158] The c-Met protein is found to be overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients and is associated with poor prognosis and limited treatment options.
Glasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigational[A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). … [L11935] Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade.